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Hepatocellular carcinoma ranks among the most common can-
cers worldwide. However, besides surgery, therapeutic strategies
remain limited and a detailed analysis and characterization of the
tumor biology will be essential in order to identify (novel) thera-
peutic targets [1]. With the development of sorafenib, a ﬁrst step
of successful targeting molecular changes in HCC has been made
but many more will have to follow in order to establish a potent
arsenal of speciﬁc therapeutic options [2].Transcriptome studies
Lately, advances in high throughput technologies in biomedical
research have led to a dramatic increase in the accessibility of
molecular insights at different levels of cancer biology such as
genome, epigenome, transcriptome, proteome, and others.
Among the diverse biological layers, the transcriptome has been
most extensively studied especially due to the successful and
broad introduction of the microarray technology. The future pros-
pect of broad disposability of deep sequencing technology will
furthermore lead to a more sensitive detection of lowly expressed
transcripts and to an increase in the number of newly identiﬁed
transcripts, but also to increase the discovery and characteriza-
tion of alternative splicing. A common goal of large scale tran-
scriptome proﬁling methods is the stratiﬁcation of patients,
eventually leading to personalized prognostic predictions and
therapeutic strategies. Also, the observation that diverse etiolo-
gies of the mostly underlying liver cirrhosis (alcohol, HBV, HCV
a.o.) are represented by different transcriptome proﬁles may be
valuable for the identiﬁcation of essential tumor targets [3]. In
particular, the ﬁeld of biomarker discovery and development
make considerable use of microarray technologies for clinical
research [4]. In breast cancer, this vision was enthusiastically
pursued over the past several years resulting in an FDA-approved
molecular signature, which may serve as an example [5].
It has repeatedly been reported that transcriptomic changes
not necessarily reﬂect changes in the corresponding proteins. In
model organisms, approximately 25% of changes in gene expres-Journal of Hepatology 20
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abundance, particularly of lowly expressed genes [6]. It has also
been observed that the transcriptome of hepatocellular carci-
noma often includes surgical material, which has not been sub-
jected to laser capture microdissection. The current data on the
transcriptome of hepatocellular carcinoma are, therefore, diluted
by cells present in the tumor microenvironment. However, a
recent publication by Villanueva et al. demonstrated the useful-
ness of integrating transcriptomic signatures with clinic-patho-
logical data in HCC and in particular demonstrated partial
reproducibility in independent data sets [7].Inﬂuencing gene expression in HCC
Multiple biological mechanisms were shown to change gene
activity in HCC. Among them are changes in chromosomal struc-
ture, genetic polymorphisms, alternative splicing, epigenetic
changes (methylation, histone modiﬁcation, miRNAs), and pro-
teomic changes. Therefore, we present a short graphical snapshot
of the liver transcriptome in HCC (Fig. 1).
Chromosomal structure and gene polymorphisms
Changes in chromosomal structure have been extensively
described. Obviously, lack or duplication of genetic regions and
thus of genes physiologically involved in liver homeostasis may
result in disturbed gene expression, which potentially favors
hepatocarcinogenesis. Several studies reported correlations of
single chromosomal gains or losses with clinicopathological fea-
tures such as tumor differentiation or prognosis (reviewed in [8]).
Furthermore, high density allelotyping using a large number of
microsatellite markers combined with gene mutation analysis
led to identiﬁcation of diverse genetic pathways involved in
HCC [9] (Table 3).
Promoter methylation
DNA methylation in the promoter region of a gene may be linked
to altered gene expression. Hypermethylation of tumor-suppres-
sor genes as well as genes involved in cell cycle regulation, apop-
tosis, DNA repair or cell adhesion, and DNA methylation plays a
crucial role in the development of a variety of cancers. Accord-
ingly, hypomethylation and consecutive activation of oncogenes
was also recognized to potentially result in cancer development.
Over the past several years, multiple genes exhibiting changes in
promoter methylation in HCC were identiﬁed (Table 4, [10]).12 vol. 56 j 990–992
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Fig. 1. Snapshot of the liver transcriptome in HCC providing a comprehensive overview on the complex interaction of diverse biological layers.
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In hepatocarcinogenesis, changes in DNAmethylation must be
considered to occur frequently and early. Furthermore, changes
in the methylation status may accompany the progression from
precancerous lesion to HCC. Finally, some of these changes were
even demonstrated in premalignant conditions, such as liver cir-
rhosis [10].
Histone modiﬁcation
Histone acetylation is dependent on the equilibrium between the
activities of histone acetyltransferases and deacetylases (HDAC),
linking acetyl groups to lysine tails. Histone hyperacetylation is
associated with a less condensed chromatin structure and thus
and unfolded, more easily transcribed DNA. In HCC, evidence
for efﬁcacy of HDAC inhibitors stems from preclinical and preli-
minary clinical phase I and II trials. Among the molecular changes
induced through changes of histone acetylation were cell cycle
related proteins, such as p21waf1 and p27kip1, and cyclin D1.
Lee et al. reported that changes in histone modiﬁcation may be
associated with patients prognosis, with higher levels of genes
involved in histone modiﬁcations in HCC with poor outcome
[11]. Thus, the concept of inhibiting histone acetylation will be
interesting to follow in the coming years [10,12].
miRNA expression
The discovery of microRNAs (miRNAs) introduced an additional
layer of complexity to transcriptome regulation. These small
RNAs are non-coding but have the capacity to target multiple
genes simultaneously. It has been well established that dysregu-
lation of miRNAs is essential for the development of various can-
cers. Given their broad transcriptome interference, these
molecules may represent promising targets for therapeutic inter-
vention. In addition, both single miRNA and small cluster of miR-
NAs may be of prognostic value in HCC [13].Conclusions
Over the past decade, modern molecular biology and the use of
high throughput genomics and transcriptomics have identiﬁed
multiple biological layers involved in transcriptome regulation.
Unraveling the tight and complex interactions between diverse992 Journal of Hepatology 201molecules, data and involved biological layers in transcriptome
of the HCC tissue will certainly result in a much better under-
standing of the underlying biology. Thus, bringing together the
diverse aspects of transcriptomic changes in HCC will lead to a
whole new perception of HCC development and subsequently
disclose novel strategies for the diagnosis and treatment of HCC.Conﬂict of interest
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